Molecular markers of prostate cancer

被引：54

作者：

Bradford, Timothy J.

Tomlins, Scott A.

Wang, Xiaoju

Chinnaiyan, Arul M. ^{[1
]}

机构：

[1] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA

[3] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

来源：

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2006年 / 24卷 / 06期

关键词：

biomarkers; prostate cancer; proteomics;

D O I：

10.1016/j.urolonc.2006.07.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although prostate-specific antigen (PSA) has evolved as a very useful tool for detection of prostate cancer, there remains an urgent need for more accurate biomarkers to diagnose prostate cancer and predict cancer-related outcomes. Recent advances in the study of proteomics and high throughput techniques have led to the discovery of many potential biomarkers for prostate cancer. This article briefly reviews the current status of PSA testing and discusses several candidate protein biomarkers for prostate cancer, as well as highlighting some recent proteomic discoveries with the potential to supplement or even replace PSA for the diagnosis and prognosis of prostate cancer. (c) 2006 Elsevier Inc. All rights reserved.

引用

收藏

页码：538 / 551

页数：14

相关论文

共 273 条

[81] DNA-based detection of prostate cancer in urine after prostatic massage [J].

Goessl, C ;

Müller, M ;

Heicappell, R ;

Krause, H ;

Straub, B ;

Schrader, M ;

Miller, K .

UROLOGY, 2001, 58 (03) :335-338

[82]

Goessl C, 2001, ANN NY ACAD SCI, V945, P51

[83]

Gong MC, 2000, MOL UROL, V4, P217

[84] Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers [J].

Gong, MC ;

Chang, SS ;

Sadelain, M ;

Bander, NH ;

Heston, WDW .

CANCER AND METASTASIS REVIEWS, 1999, 18 (04) :483-490

[85]

Gonzalgo ML, 2003, CLIN CANCER RES, V9, P2673

[86] The Early Detection Research Network surface-enhanced laser desorption and ionization prostate cancer detection study: a study in biomarker validation in genitourinary oncology [J].

Grizzle, WE ;

Semmes, OJ ;

Basler, J ;

Izbicka, E ;

Feng, ZD ;

Kagan, J ;

Adam, BL ;

Troyer, D ;

Srivastava, S ;

Thornquist, M ;

Zhang, Z ;

Thompson, IM .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004, 22 (04) :337-343

[87] Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer [J].

Gu, Z ;

Thomas, G ;

Yamashiro, J ;

Shintaku, IP ;

Dorey, F ;

Raitano, A ;

Witte, ON ;

Said, JW ;

Loda, M ;

Reiter, RE .

ONCOGENE, 2000, 19 (10) :1288-1296

[88] Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism [J].

Gu, ZN ;

Yamashiro, J ;

Kono, E ;

Reiter, RE .

CANCER RESEARCH, 2005, 65 (20) :9495-9500

[89] Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml [J].

Haese, A ;

Graefen, M ;

Steuber, T ;

Becker, C ;

Pettersson, K ;

Piironen, T ;

Noldus, J ;

Huland, H ;

Lilja, H .

PROSTATE, 2001, 49 (02) :101-109

[90] Human glandular kallikrein 2: A potential serum marker for predicting the organ confined versus nonorgan confined growth of prostate cancer [J].

Haese, A ;

Becker, C ;

Noldus, J ;

Graefen, M ;

Huland, E ;

Huland, H ;

Lilja, H .

JOURNAL OF UROLOGY, 2000, 163 (05) :1491-1497

← 4 5 6 7 8 9 10 11 12 13 →